Study of GL701 in Men With Systemic Lupus Erythematosus
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Lupus flares and other symptoms associated with systemic lupus erythematosus (SLE) may be
caused by a deficiency of dehydroepiandrosterone (DHEA). GL701 is an investigational new drug
meant to enhance DHEA levels. This study is designed to evaluate both the safety and efficacy
of GL701 in male lupus patients.